CAS 21679-14-1|Fludarabine

Introduction：Basic information about CAS 21679-14-1|Fludarabine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Fludarabine BiologicalActivity
3. Chemical & Physical Properties
4. Toxicological Information
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
MUTATION DATA
5. Safety Information
6. Articles87
7. Synonyms

Common Name	Fludarabine
CAS Number	21679-14-1	Molecular Weight	285.232
Density	2.2±0.1 g/cm3	Boiling Point	747.3±70.0 °C at 760 mmHg
Molecular Formula	C₁₀H₁₂FN₅O₄	Melting Point	265-268ºC
MSDS	ChineseUSA	Flash Point	405.8±35.7 °C
Symbol	GHS07	Signal Word	Warning

Names

Name	(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Synonym	More Synonyms

Fludarabine BiologicalActivity

Description	Fludarabine(NSC 118218), a DNA synthesis inhibitor, is a chemotherapy drug used in the treatment of hematological malignancies.Target:Fludarabine or fludarabine ph osphate (Fludara) is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). It is a purine analog, which interferes with DNA synthesis. Fludarabine is highly effective in the treatment of chronic lymphocytic leukemia, producing higher response rates than alkylating agents such as chlorambucil alone.Fludarabine is a purine analog, and can be given both orally and intravenously. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. It is active against both dividing and resting cells. Being phosphorylated, fludarabine is ionized at physiologic pH and is effectually trapped in blood. This provides some level of specificity for blood cells, both cancerous and healthy. Fludarabine is associated with the development of severe autoimmune hemolytic anemia in a proportion of patients. Difficulties are often encountered when harvesting peripheral blood stem cells from patients previously treated with fludarabine.
Related Catalog	Signaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogResearch Areas >>Cancer
References	[1]. Rai KR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7. [2]. Tournilhac O, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11.

Description

Fludarabine(NSC 118218), a DNA synthesis inhibitor, is a chemotherapy drug used in the treatment of hematological malignancies.Target:Fludarabine or fludarabine ph osphate (Fludara) is a chemotherapy drug used in the treatment of hematological malignancies (cancers of blood cells such as leukemias and lymphomas). It is a purine analog, which interferes with DNA synthesis. Fludarabine is highly effective in the treatment of chronic lymphocytic leukemia, producing higher response rates than alkylating agents such as chlorambucil alone.Fludarabine is a purine analog, and can be given both orally and intravenously. Fludarabine inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase. It is active against both dividing and resting cells. Being phosphorylated, fludarabine is ionized at physiologic pH and is effectually trapped in blood. This provides some level of specificity for blood cells, both cancerous and healthy. Fludarabine is associated with the development of severe autoimmune hemolytic anemia in a proportion of patients. Difficulties are often encountered when harvesting peripheral blood stem cells from patients previously treated with fludarabine.

Related Catalog

Signaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogResearch Areas >>Cancer

References

[1]. Rai KR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000 Dec 14;343(24):1750-7.

[2]. Tournilhac O, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004 Jan 1;103(1):363-5. Epub 2003 Sep 11.

Chemical & Physical Properties

Density	2.2±0.1 g/cm3
Boiling Point	747.3±70.0 °C at 760 mmHg
Melting Point	265-268ºC
Molecular Formula	C₁₀H₁₂FN₅O₄
Molecular Weight	285.232
Flash Point	405.8±35.7 °C
Exact Mass	285.087341
PSA	139.54000
LogP	-0.40
Vapour Pressure	0.0±2.6 mmHg at 25°C
Index of Refraction	1.876
InChIKey	HBUBKKRHXORPQB-FJFJXFQQSA-N
SMILES	Nc1nc(F)nc2c1ncn2C1OC(CO)C(O)C1O
Storage condition	2-8°C
Water Solubility	DMF: 20 mg/mL, clear, faintly yellow

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: AU6207000

CHEMICAL NAME :: Adenine, 9-beta-D-arabinofuranosyl-2-fluoro-

CAS REGISTRY NUMBER :: 21679-14-1

LAST UPDATED :: 198909

DATA ITEMS CITED :: 4

MOLECULAR FORMULA :: C10-H12-F-N5-O4

MOLECULAR WEIGHT :: 285.27

WISWESSER LINE NOTATION :: T56 BN DN FN HNJ GF IZ D- BT5OTJ CQ DQ E1Q

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 375 mg/kg

TOXIC EFFECTS :: Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: DNA inhibition

MUTATION DATA

TYPE OF TEST :: Mutation in mammalian somatic cells

TEST SYSTEM :: Rodent - hamster Ovary

DOSE/DURATION :: 100 umol/L

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 210,291,1989

Safety Information

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Faceshields;Gloves
Hazard Codes	Xn
Risk Phrases	R23/24/25;R36/37/38;R39
Safety Phrases	S26-S36/37-S45
RIDADR	NONH for all modes of transport
WGK Germany	3
RTECS	AU6207000

Articles87

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

J. Sci. Ind. Res. 65(10) , 808, (2006)

Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI typ...

Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

J. Med. Chem. 51 , 6740-51, (2008)

The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ...

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

Drug Metab. Dispos. 36 , 1385-405, (2008)

We present herein a compilation and trend analysis of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic ...

Synonyms

UNII-P2K93U8740

9-b-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine

9-β-D-Arabinofuranosyl-2-fluoroadenine

MFCD00132942

9H-Purin-6-amine, 9-β-D-arabinofuranosyl-2-fluoro-

Fludarabine des-phosphate

9-(β-D-Arabinofuranosyl)-2-fluoro-9H-purin-6-amine

9-b-D-Arabinofuranosyl-2-fluoroadenine

(2R,3S,4S,5R)-2-(6-Amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

Fludarabine

EINECS 244-525-5

2-Fluoro-9-b-D-arabinofuranosyladenine

F-Ara-A

2-Fluoroadenine-9-β-D-arabinofuranoside

2-F-araA

Adenine, 9-β-D-arabinofuranosyl-2-fluoro-

2-Fluorovidarabine

Recommended......